275 related articles for article (PubMed ID: 23847702)
21. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
Keiser P; Nassar N; White C; Koen G; Moreno S
HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
[TBL] [Abstract][Full Text] [Related]
22. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
Ngayo MO; Oluka M; Bulimo WD; Okalebo FA
Sci Rep; 2021 Nov; 11(1):22071. PubMed ID: 34764325
[TBL] [Abstract][Full Text] [Related]
23. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
[TBL] [Abstract][Full Text] [Related]
24. Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
Ramachandran G; Kumar AK; Ponnuraja C; Ramesh K; Rajesh L; Chandrasekharan C; Swaminathan S
Indian J Med Res; 2013 Dec; 138(6):955-61. PubMed ID: 24521642
[TBL] [Abstract][Full Text] [Related]
25. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
Ayele TA; Worku A; Kebede Y; Alemu K; Kasim A; Shkedy Z
Syst Rev; 2017 Aug; 6(1):173. PubMed ID: 28841912
[TBL] [Abstract][Full Text] [Related]
26. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Chetty T; Thorne C; Coutsoudis A
PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
[TBL] [Abstract][Full Text] [Related]
27. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Abgrall S; Ingle SM; May MT; Costagliola D; Mercie P; Cavassini M; Reekie J; Samji H; Gill MJ; Crane HM; Tate J; Sterling TR; Antinori A; Reiss P; Saag MS; Mugavero MJ; Phillips A; Manzardo C; Wasmuth JC; Stephan C; Guest JL; Gomez Sirvent JL; Sterne JA;
AIDS; 2013 Mar; 27(5):803-13. PubMed ID: 23719350
[TBL] [Abstract][Full Text] [Related]
28. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
[TBL] [Abstract][Full Text] [Related]
29. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
[TBL] [Abstract][Full Text] [Related]
30. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
Ananworanich J; Moor Z; Siangphoe U; Chan J; Cardiello P; Duncombe C; Phanuphak P; Ruxrungtham K; Lange J; Cooper DA
AIDS; 2005 Jan; 19(2):185-92. PubMed ID: 15668544
[TBL] [Abstract][Full Text] [Related]
31. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
Manosuthi W; Sungkanuparph S; Vibhagool A; Rattanasiri S; Thakkinstian A
HIV Med; 2004 Mar; 5(2):105-9. PubMed ID: 15012650
[TBL] [Abstract][Full Text] [Related]
32. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
[TBL] [Abstract][Full Text] [Related]
33. Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
Lowenthal ED; Ellenberg JH; Machine E; Sagdeo A; Boiditswe S; Steenhoff AP; Rutstein R; Anabwani G; Gross R
JAMA; 2013 May; 309(17):1803-9. PubMed ID: 23632724
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and durability of nevirapine in antiretroviral drug näive patients.
Lange JM
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S40-52. PubMed ID: 14562857
[TBL] [Abstract][Full Text] [Related]
35. Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
Sanjeeva GN; Sukanya V; Pavithra HB; Dodderi SK; Rewari BB; Govindaraj M; Shivananda S; Premalatha R
AIDS Care; 2015; 27(5):655-9. PubMed ID: 25517472
[TBL] [Abstract][Full Text] [Related]
36. Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Mazanderani AH; Murray TY; Sherman GG; Snyman T; George J; Avenant T; Goga AE; Pepper MS; du Plessis N
J Int AIDS Soc; 2019 Jun; 22(6):e25284. PubMed ID: 31215757
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM;
AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009
[TBL] [Abstract][Full Text] [Related]
38. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
Sathia L; Obiorah I; Taylor G; Kon O; O'Donoghue M; Gibbins S; Walsh J; Winston A
AIDS Res Hum Retroviruses; 2008 Jul; 24(7):897-901. PubMed ID: 18671475
[TBL] [Abstract][Full Text] [Related]
39. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.
Núñez M; Soriano V; Martín-Carbonero L; Barrios A; Barreiro P; Blanco F; García-Benayas T; González-Lahoz J
HIV Clin Trials; 2002; 3(3):186-94. PubMed ID: 12032877
[TBL] [Abstract][Full Text] [Related]
40. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]